This review was conducted to consider the safety of the ten-valent pneumococcal conjugate vaccine (PCV-10; Synflorix®) and its effectiveness in preventing pneumococcal disease, in particular invasive pneumococcal disease (IPD), in target age groups and the wider community when included in the childhood national immunisation schedule.

The impact on otitis media incidence and non-invasive pneumococcal infections is also considered. Literature published between January 2013 and November 2016 is evaluated.